Gemcitabine-Coumarin-Biotin Conjugates: A Target Specific Theranostic Anticancer Prodrug
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Maiti, Sukhendu | - |
dc.contributor.author | Park, Nayoung | - |
dc.contributor.author | Han, Ji Hye | - |
dc.contributor.author | Jeon, Hyun Mi | - |
dc.contributor.author | Lee, Jae Hong | - |
dc.contributor.author | Bhuniya, Sankarprasad | - |
dc.contributor.author | Kang, Chulhun | - |
dc.contributor.author | Kim, Jong Seung | - |
dc.date.accessioned | 2021-09-06T03:25:25Z | - |
dc.date.available | 2021-09-06T03:25:25Z | - |
dc.date.created | 2021-06-14 | - |
dc.date.issued | 2013-03-20 | - |
dc.identifier.issn | 0002-7863 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/103724 | - |
dc.description.abstract | We present here, the design, synthesis, spectroscopic characterization, and in vitro biological assessment of a gemcitabine-coumarin-biotin conjugate (5). Probe 5 is a multifunctional molecule composed of a thiol-specific cleavable disulfide bond, a coumarin moiety as a fluorescent reporter, gemcitabine (GMC) as a model active drug, and biotin as a cancer-targeting unit. Upon addition of free thiols that are relatively abundant in tumor cells, disulfide bond cleavage occurs as well as active drug GMC release and concomitantly fluorescence intensity increases. Confocal microscopic experiments reveal that 5 is preferentially taken up by A549 cells rather than WI38 cells. Fluorescence-based colocalization studies using lysosome- and endoplasmic reticulum-selective dyes suggest that thiol-induced disulfide cleavage of 5 occur in the lysosome possibly via receptor-mediated endocytosis. The present drug delivery system is a new theranostic agent, wherein both a therapeutic effect and drug uptake can be readily monitored at the subcellular level by two photon fluorescence imaging. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | AMER CHEMICAL SOC | - |
dc.subject | DRUG-DELIVERY | - |
dc.subject | GOLD NANOPARTICLES | - |
dc.subject | CANCER | - |
dc.subject | RECEPTOR | - |
dc.subject | RELEASE | - |
dc.title | Gemcitabine-Coumarin-Biotin Conjugates: A Target Specific Theranostic Anticancer Prodrug | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, Jong Seung | - |
dc.identifier.doi | 10.1021/ja401350x | - |
dc.identifier.scopusid | 2-s2.0-84875480413 | - |
dc.identifier.wosid | 000316774100053 | - |
dc.identifier.bibliographicCitation | JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, v.135, no.11, pp.4567 - 4572 | - |
dc.relation.isPartOf | JOURNAL OF THE AMERICAN CHEMICAL SOCIETY | - |
dc.citation.title | JOURNAL OF THE AMERICAN CHEMICAL SOCIETY | - |
dc.citation.volume | 135 | - |
dc.citation.number | 11 | - |
dc.citation.startPage | 4567 | - |
dc.citation.endPage | 4572 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Chemistry | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Multidisciplinary | - |
dc.subject.keywordPlus | DRUG-DELIVERY | - |
dc.subject.keywordPlus | GOLD NANOPARTICLES | - |
dc.subject.keywordPlus | CANCER | - |
dc.subject.keywordPlus | RECEPTOR | - |
dc.subject.keywordPlus | RELEASE | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.